Filters: Author is Baiget, M [Clear All Filters]
Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. British journal of clinical pharmacology. 2010;70(2):268-72.
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British journal of cancer. 2011;105(1):53-7.
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast cancer research and treatment. 2010;119(1):33-8.
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(6):1788-96.
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(20):3468; author reply 3468-9.
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British journal of cancer. 2008;99(7):1050-5.
Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. International journal of radiation oncology, biology, physics. 2011;81(5):1319-27.
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. The pharmacogenomics journal. 2012.
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. Journal of cancer research and clinical oncology. 2010;136(11):1681-9.